5. Risk and Benefit of Androgen Deprivation Therapy in Prostate Cancer

  1. Mario Maggi
  1. Giovanni Corona1,2,
  2. Mauro Gacci3,
  3. Elisabetta Baldi3,
  4. Gianni Forti4 and
  5. Mario Maggi5

Published Online: 29 NOV 2011

DOI: 10.1002/9781119963820.ch5

Hormonal Therapy for Male Sexual Dysfunction

Hormonal Therapy for Male Sexual Dysfunction

How to Cite

Corona, G., Gacci, M., Baldi, E., Forti, G. and Maggi, M. (2011) Risk and Benefit of Androgen Deprivation Therapy in Prostate Cancer, in Hormonal Therapy for Male Sexual Dysfunction (ed M. Maggi), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781119963820.ch5

Editor Information

  1. Sexual Medicine & Andrology, University of Florence, Florence, Italy

Author Information

  1. 1

    Endocrinology Unit, Medical Department, Azienda Usl Bologna, Maggiore-Bellaria Hospital, Bologna, Italy

  2. 2

    Department of Clinical Physiopathology, University of Florence, Florence, Italy

  3. 3

    Department of Urology, University of Florence, Florence, Italy

  4. 4

    Endocrinology Unit, Department of Clinical Physiopathology, University of Florence, Florence, Italy

  5. 5

    Sexual Medicine & Andrology, University of Florence, Florence, Italy

Publication History

  1. Published Online: 29 NOV 2011
  2. Published Print: 15 DEC 2011

ISBN Information

Print ISBN: 9780470657607

Online ISBN: 9781119963820

SEARCH

Keywords:

  • Prostate cancer;
  • androgens;
  • hypogonadism;
  • cardiovascular diseases;
  • osteoporosis;
  • bone fracture;
  • sexual dysfunction

Summary

Although androgen deprivation therapy (ADT) is the cornerstone in the treatment of advanced and metastatic PC, its use improves disease-free and overall survival only in combination with primary radiation for locally advanced or high-risk diseases and as adjuvant therapy for positive lymphnode diseases after prostatectomy. Since androgens regulate fat distribution, insulin sensitivity, and lipid metabolism, recent publications suggest that ADT may increase cardiovascular problems, morbidity and mortality. Physicians should weigh the risk/benefit ratio before prescribing ADT.